# Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

> **NCT05411107** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Bronchial Epithelial Dysplasia
- Chronic Obstructive Pulmonary Disease
- Lung Carcinoma
- Stage I Lung Cancer AJCC v8
- Stage II Lung Cancer AJCC v8
- Tobacco-Related Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bronchial Brush Biopsy
- **PROCEDURE:** Bronchoscopy
- **DRUG:** Iloprost
- **DRUG:** Placebo Administration
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05411107
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Agent is not available
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411107, "Oral Iloprost for the Prevention of Lung Cancer In Former Smokers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05411107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*